TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cardiac ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardiac performance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in urinary PGE-M level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood Lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Pre-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of variation of lumbar BMD on DEXA scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: ED90 for bolus phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of EuroQol-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline of Condition Specific Oral Impacts on Daily Performance Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: composite of all causes of death, new myocardial infarction, or severe myocardial ischemia requiring urgent repeat target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Weekly Average Daily NPRS (Average Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measurement using VNRS Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intro-ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of NOMAC and serum concentrations of E2 and E1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ultrasonographic muscle thickness measurement of lumbar multifidus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Progression of disease within 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Training time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Worsening in Severity of Gastrointestinal Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Produce time for the coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Flexor and Extensor cervical muscles holding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck disability questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual analogue scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of molecular markers associated with SP resistance at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of molecular markers associated with SP resistance at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in ALSFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder status based on IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Motor Unit Innervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor Unit Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proprioception Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coronary artery stenosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Alive and Progression-free
Endpoint domain: Mortality/survival
Primary endpoint: Presence of germline ITK mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between ITK mutations with specific clinical or histopathological features of HL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium intake in mg per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and average size of rectal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change on HAMD21 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modulation of immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum serum concentration of tapentadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the observed maximum serum concentration of tapentadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve of tapentadol from time 0 to infinite time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Floor Muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of cytology specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oedema reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of parent training content on the PYCC website
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of uses of parent training content on the PYCC website
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC(0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR (Sustained Virologic Response) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients receiving any allogeneic blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Hematology Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to recovery of peripheral capillary oxygen saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of confirmed diagnoses (new cases of CRC or PaCa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Event Free Survival (EFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Kessler 10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive Emotion Regulation Questionnaire-Short
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative dose eliciting 20% fall in FEV1 (PD20FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Asthma symptom score as proposed by Hoggs et al
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 12-Month Survival
Endpoint domain: Mortality/survival
Primary endpoint: Medication related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Economic impact
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Absolute Change From Baseline in Facial Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cognition status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in post-operative swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Clearance of Anidulafungin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nausea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time Difference Between Cauterizing and Detaching Uterine Attachments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tumour resectability at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Procedural mortality
Endpoint domain: Mortality/survival
Primary endpoint: Need for cardiac surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Development of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of small intestinal mucosal involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Technical Success (Retrieval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success (Retrieval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events Through 30 Days Post Retrieval
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ribavirin plasma trough concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Device thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined outcome of all-cause mortality, bleeding, stroke, or Device thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Transplant nephrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Urinary Sodium Excretion (UNaV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Target Segment Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Change in Total ADHD Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adherence to Clinical Practice Guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handgrip strength value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of aromatase target gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in serum levels of PGE2 (prostaglandin E2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Weekly Epoetin Dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: renal function of recipient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Subjects Reporting Headache Pain Freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Absence of Most Bothersome Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep measure
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of patients reaching an absolute CD4 count over 200/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnetic resonance imaging results of brain tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Multivitamin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Disease Control (Freedom From Disease Progression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal body fat measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of patients receiving an internal drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effectiveness of 3D printed videolaryngoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose Limiting Toxicity (DLT) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of post ERCP pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: IOP fluctuation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death of newborns with COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Vertical gingival display
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nose-U-lip-length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper anterior teeth retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper incisors extrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time (RT) to correct responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Omission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Commission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: modified Rankin Scale 0-1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Qualitative detection of ribosomal RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self selected over ground gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of social communication skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: AUC plasma polyphenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Miscarriage before 20 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Combined Dermatologist Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of Combined Ophthalmologist Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of Combined Dermatologist and Ophthalmologist Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Dermatologist and Ophthalmologist Score (Modified)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically relevant pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to Mild Cognitive Impairment
Endpoint domain: Mortality/survival
Primary endpoint: Glucose monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastrointestinal Symptom Responsiveness Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in AP-CCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Browning of subcutaneous white adipose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Subjects Cured of Reflux Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Depth of Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of freezing of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: AUCτ,ss for Evogliptin and Glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of autistic child's behaviour or condition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to first symptomatic or asymptomatic AFIB event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of 2010-2011 seasonal trivalent vaccine (TIV)
Endpoint domain: Adverse events/effects
Primary endpoint: Immune responses to each component of TIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persistence of anti-HAI responses to H1N12009
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary cortisol response to repeated acute psychosocial stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical Global Impression - Global Improvement (CGI -I) Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in severity of auditory verbal hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 68Ga-PSMA-11 PET for nodal metastases detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of 68Ga-PSMA-11 PET for nodal metastases detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of 68Ga-PSMA-11 PET for nodal metastases detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of 68Ga-PSMA-11 PET for nodal metastases detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Conjunctival Redness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score comparison between treated and placebo groups
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor cortical excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of anastomoses with immediate sealing of the suture line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of rapid HIV testing program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Signs and Symptoms of Cutaneous Irritation Total Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUC (area under the plasma concentration time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ss (maximum plasma concentration at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax ss (time to Cmax at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inducibility of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustainability of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Management of wound exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wound Healing progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Per wound skin conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: level of corticospinal excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pathological complete or near-complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resection rate of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of the exercise intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in scores of KPC Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Conflict tactics scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttraumatic stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes from baseline in prothrombin time (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline in activated partial thromboplastin time (aPTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete occlusion of target aneurysm or fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic death or ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Colony Forming Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain in the knee at 8 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes